Publication: Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi
Issued Date
2021-02-22
Resource Type
ISSN
18732518
0264410X
0264410X
Other identifier(s)
2-s2.0-85099711747
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.39, No.8 (2021), 1272-1282
Suggested Citation
Fulgence Niyibitegeka, Arthorn Riewpaiboon, Sitaporn Youngkong, Montarat Thavorncharoensap Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi. Vaccine. Vol.39, No.8 (2021), 1272-1282. doi:10.1016/j.vaccine.2021.01.031 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76276
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi
Other Contributor(s)
Abstract
Background: In Burundi, diarrhea is the third leading cause of mortality among children under five years of age. This study conducted an economic analysis of rotavirus vaccination program in Burundi. Methods: A Markov model was constructed to simulate clinical and economic outcomes for the 2019 birth cohort for a period of 5 years. Empirical costing data were collected. ICER per episode averted, ICER per death averted, ICER per DALY averted, net present value, and budget impact were estimated for 4 brands of WHO pre-qualified rotavirus vaccines. One-way and probabilistic sensitivity analysis as well as threshold analysis were performed. Results: For the base case, while all four WHO pre-qualified rotavirus vaccines were cost-effective (ICER < 3 GDP per capita), three of them (i.e. Rotarix, Rotavac and Rotasiil) were very cost-effective (ICER <1 GDP per capita) from both the provider and societal perspectives. The vaccines were still very cost-effective at a price increase of up to US$ 5.09, US$ 3.16, US$ 3.89, and US$ 2.69 for Rotarix, RotaTeq, Rotavac, and Rotasiil, respectively. Probabilistic sensitivity analysis indicated that vaccination programs with Rotarix, RotaTeq, Rotavac, and Rotasiil are cost-effective at a probability of 93.8%, 27%, 99.1%, and 92.7%, respectively. All vaccination programs were cost-beneficial with a net present value in the range of US$ 5,214,912 and US$ 11,135,997.The budget required to run the vaccination program, estimated with break-even prices, ranged between US$ 42,249,498 and US$ 53,487,935 for a 5-year time period. When compared to the GDP of Burundi in 2019, these are are less than 2%. Conclusion: The rotavirus vaccine is good value for money. Findings from this study offer evidence on potential economic benefits as well as the required budget for different rotavirus vaccination programs, which could be useful for future planning related to rotavirus vaccine coverage in Burundi after graduation from GAVI.